Lucid Joins Forces with Academy Award Nominees Timothée Chalamet and Director James Mangold in Exhilarating New Brand Story

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Lucid Joins Forces with Academy Award Nominees Timothée Chalamet and Director James Mangold in Exhilarating New Brand Story

Canaccord Genuity on Lucid Diagnostics Inc (LUCD): 'we believe the stock does not reflect the company's long-term growth potential'

September 5, 2025 5:16 AM EDT

(Updated - September 5, 2025 5:32 AM EDT)

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)

The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Intraday on Thursday, September 4, MolDX-participating Medicare Administrative Contractors (MACs) convened a MolDX Contractor Advisory Committee (CAC)... More